Download PDF
Z Gastroenterol 2004; 42(8): 687-691
DOI: 10.1055/s-2004-813438
Leitlinie

© Karl Demeter Verlag im Georg Thieme Verlag KG Stuttgart · New York

Standardtherapie der chronischen Hepatitis B

Standard Treatment of Chronic Hepatitis BM. P. Manns1 , W. H. Caselmann2 , K. H. Wiedmann3 , H. Wedemeyer1
  • 1Medizinische Hochschule Hannover, Abt. Gastroenterologie, Hepatologie und Endokrinologie, Hannover
  • 2Bayerisches Staatsministerium für Umwelt, Gesundheit und Verbraucherschutz, München
  • 3Krankenhaus Barmherzige Brüder, Medizinische Klinik, Regensburg
Further Information

Publication History





Publication Date:
16 August 2004 (online)

Also available at
    Permissions and Reprints

Ziel der Therapie/Definition des Behandlungserfolgs

Konsens

Kriterien eines Therapieansprechens sind:

  • biochemisch: ALT-Normalisierung

  • virologisch: HBe-Serokonversion, HBV-DNA-Negativierung im Hybridisierungsassay oder ein Abfall der HBV-DNA auf < 105 Kopien/ml in quantitativen PCR-Assays, HBsAg-Verlust

  • histologisch: Verbesserung der histologischen entzündlichen Aktivität (Therapieende), Verbesserung histologischer Fibrose-Scores (Therapieende)

  • potenzielle Langzeiteffekte: Verhinderung einer hepatischen Dekompensation, die Verhinderung der Entwicklung eines HCC und ein verbessertes Überleben.

Erläuterung

Endpunkte der meisten randomisierten Therapiestudien der Hepatitis B waren dauerhafte Normalisierungen der Transaminasen und HBe-Serokonversionen. Patienten, die diese Erfolgsparameter erfüllten, zeigten eine geringere Rate hepatischer Dekompensationen, eine niedrige Rate von HCC-Entstehungen sowie ein verbessertes Langzeitüberleben [1] [2] [3] [4]. Die HBV-Viruslast wurde in den Studien der 90er-Jahre zunächst nur mit Hybridisierungsassays bestimmt (Cut-Off ca. 100 000 - 200 000 Kopien/ml); sensitivere quantitative PCR-basierte Methoden sind erst seit wenigen Jahren im routinemäßigen Einsatz. Da eine dauerhaft niedrig replikative Hepatitis B mit einem milden Verlauf assoziiert ist, wird ein Abfall der HBV-DNA unter einen Wert von 105 Kopien/ml als Therapieansprechen angesehen. Das histologische Therapieansprechen, welches zur Zulassung der neuen Nukleosidanaloga gefordert wurde, ist meist nur am Ende einer Therapie bestimmt worden. Daten zum histologischen Therapieansprechen im Langzeitverlauf nach Therapieende liegen nur für einige Interferonstudien vor und fehlen bisher für die Behandlung der Hepatitis B mit Nukleosidanaloga.

Literatur

  • 1 Lok A S, Heathcote E J, Hoofnagle J H. Management of hepatitis B: 2000 - summary of a workshop.  Gastroenterology. 2001;  120 (7) 1828-1853 (Ia)
    PubMedGoogle Scholar
  • 2 Niederau C, Heintges T, Lange S. et al . Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.  N Engl J Med. 1996;  334 (22) 1422-1427 (IIa)
    CrossrefPubMedGoogle Scholar
  • 3 Craxi A, Di Bona D, Camma C. Interferon alfa for HBeAg positive chronic hepatitis B: systemativ review.  J Hepatol. 2003;  39 (Suppl. 1) 99-105 (Ia)
    PubMedGoogle Scholar
  • 4 Hoofnagle J H, Di Bisceglie A M. The treatment of chronic viral hepatitis.  N Engl J Med. 1997;  336 (5) 347-356
    PubMedGoogle Scholar
  • 5 Pastore G, Santantonio T, Monno L. et al . Permanent inhibition of viral replication induced by low dosage of human leukocyte interferon in patients with chronic hepatitis B.  Hepatogastroenterology. 1988;  35 (2) 57-61 (Ib)
    PubMedGoogle Scholar
  • 6 Fattovich G, Brollo L, Boscaro S. et al . Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B.  J Hepatol. 1989;  9 (3) 331-337 (Ib)
    CrossrefPubMedGoogle Scholar
  • 7 Brook M G, Chan G, Yap I. et al . Randomised controlled trial of lymphoblastoid interferon alfa in Europid men with chronic hepatitis B virus infection.  BMJ. 1989;  299 (6700) 652-656 (Ib)
    CrossrefPubMedGoogle Scholar
  • 8 Waked I, Amin M, Abd e F. et al . Experience with interferon in chronic hepatitis B in Egypt.  J Chemother. 1990;  2 (5) 310-318 (II)
    PubMedGoogle Scholar
  • 9 Lin S M, Sheen I S, Chien R N. et al . Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection.  Hepatology. 1999;  29 (3) 971-975 (II)
    CrossrefPubMedGoogle Scholar
  • 10 Korenman J, Baker B, Waggoner J. et al . Long-term remission of chronic hepatitis B after alfa-interferon therapy.  Ann Intern Med. 1991;  114 (8) 629-634 (III)
    PubMedGoogle Scholar
  • 11 Hsu Y S, Chien R N, Yeh C T. et al . Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.  Hepatology. 2002;  35 (6) 1522-1527 (III)
    CrossrefPubMedGoogle Scholar
  • 12 Lau D T, Everhart J, Kleiner D E. et al . Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa.  Gastroenterology. 1997;  113 (5) 1660-1667 (Ib)
    PubMedGoogle Scholar
  • 13 Krogsgaard K, Bindslev N, Christensen E. et al . The treatment effect of alfa interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).  J Hepatol. 1994;  21 (4) 646-655 (Ia)
    CrossrefPubMedGoogle Scholar
  • 14 Cooksley W G, Piratvisuth T, Wanf Y J. et al . 40Kd Peg-Interferon alfa 2A (Pegasys) efficacy and safety results, from a phase II, randomized actively controlled, multi-center study in the treatment of HBeAg positive chronic hepatitis B.  J Viral Hepat. 2003;  10 298-305 (Ib)
    CrossrefPubMedGoogle Scholar
  • 15 Dienstag J L, Schiff E R, Wright T L. et al . Lamivudine as initial treatment for chronic hepatitis B in the United States.  N Engl J Med. 1999;  341 (17) 1256-1263 (Ib)
    CrossrefPubMedGoogle Scholar
  • 16 Lai C L, Chien R N, Leung N W. et al . A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.  N Engl J Med. 1998;  339 (2) 61-68 (Ib)
    CrossrefPubMedGoogle Scholar
  • 17 Kweon Y O, Goodman Z D, Dienstag J L. et al . Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.  J Hepatol. 2001;  35 (6) 749-755 (II)
    CrossrefPubMedGoogle Scholar
  • 18 Dienstag J L, Goldin R D, Heathcote E J. et al . Histological outcome during long-term lamivudine therapy.  Gastroenterology. 2003;  124 (1) 105-117 (Ib)
    CrossrefPubMedGoogle Scholar
  • 19 Dienstag J L, Schiff E R, Mitchell M. et al . Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.  Hepatology. 1999;  30 (4) 1082-1087 (IIb)
    CrossrefPubMedGoogle Scholar
  • 20 Liaw Y F, Leung N W, Chang T T. et al . Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.  Gastroenterology. 2000;  119 (1) 172-180 (Ib)
    CrossrefPubMedGoogle Scholar
  • 21 Leung N W, Lai C L, Chang T T. et al . Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.  Hepatology. 2001;  33 (6) 1527-1532 (Ib)
    CrossrefPubMedGoogle Scholar
  • 22 Dienstag J L, Cianciara J, Karayalcin S. et al . Durability of serologic response after lamivudine treatment of chronic hepatitis B.  Hepatology. 2003;  37 (4) 748-755 (IIa)
    CrossrefPubMedGoogle Scholar
  • 23 Honkoop P, de Man R A, Niesters H G. et al . Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy.  Hepatology. 2000;  32 (3) 635-639 (III)
    CrossrefPubMedGoogle Scholar
  • 24 Peters M G, Singer G, Howard T. et al . Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.  Transplantation. 1999;  68 (12) 1912-1914 (III)
    PubMedGoogle Scholar
  • 25 Lai C L, Dienstag J, Schiff E. et al . Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.  Clin Infect Dis. 2003;  36 (6) 687-696 (III)
    CrossrefPubMedGoogle Scholar
  • 26 Lau D T, Khokhar M F, Doo E. et al . Long-term therapy of chronic hepatitis B with lamivudine.  Hepatology. 2000;  32 (4 Pt 1) 828-834 (III)
    CrossrefPubMedGoogle Scholar
  • 27 Peters M, Schiff E, Benhamou Y. et al . Adefovir dipivoxil (ADV) demonstrates anti-viral efficacy and clinical benefit in the treatment of lamivudine resistant (LAM-R) chronic HBV: An analysis of four clinical trials.  Gastroenterology. 2002;  123 (1) 69 (Ia)
    PubMedGoogle Scholar
  • 28 Schiff E R, Lai C L, Hadziyannis S. et al . Behalf of the Adefovir Dipovoxil Study 435 International Investigators Group. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients.  Hepatology. 2003;  38 1419-1427 (IIa)
    PubMedGoogle Scholar
  • 29 Perrillo R P, Wright T, Rakela J. et al . A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.  Hepatology. 2001;  33 (2) 424-432 (IIa)
    CrossrefPubMedGoogle Scholar
  • 30 Hann H W, Fontana R J, Wright T. et al . A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis.  Liver Transpl. 2003;  9 (1) 49-56 (IIa)
    CrossrefPubMedGoogle Scholar
  • 31 Marcellin P, Chang T T, Lim S G. et al . Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.  N Engl J Med. 2003;  348 (9) 808-816 (Ib)
    CrossrefPubMedGoogle Scholar
  • 32 Westland C, Yang H L, Delaney W. et al . Resistance monitoring in two phase III clinical studies of adefovir dipivoxil for the treatment of chronic hepatitis B infection.  Hepatology. 2003;  38 96-103 (IIa)
    CrossrefPubMedGoogle Scholar
  • 33 Manns M P, Neuhaus P, Atkinson G F. et al . Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study.  Transpl Infect Dis. 2001;  3 (1) 16-23 (IIa)
    CrossrefPubMedGoogle Scholar
  • 34 Wedemeyer H, Boker K H, Pethig K. et al . Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial.  Transplantation. 1999;  68 (10) 1503-1511 (IIa)
    PubMedGoogle Scholar
  • 35 Hadziyannis S J, Manesis E K, Papakonstantinou A. Oral ganciclovir treatment in chronic hepatitis B virus infection: a pilot study.  J Hepatol. 1999;  31 (2) 210-214 (Ib)
    PubMedGoogle Scholar
  • 36 Gish R G, Lau J Y, Brooks L. et al . Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients.  Hepatology. 1996;  23 (1) 1-7 (III)
    PubMedGoogle Scholar
  • 37 Bozkaya H, Yurdaydin C, Bozdayi A M. et al . Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.  Clin Infect Dis. 2002;  35 (8) 960-965 (IIa)
    CrossrefPubMedGoogle Scholar
  • 38 Van Bommel F, Schernick A, Hopf U. et al . Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.  Gastroenterology. 2003;  124 (2) 586-587 (III)
    PubMedGoogle Scholar
  • 39 Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.  N Engl J Med. 2003;  348 (2) 177-178 (III)
    CrossrefPubMedGoogle Scholar
  • 40 Van Bommel F, Wunsche T, Schurmann D. et al . Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication.  Hepatology. 2002;  36 (2) 507-508 (III)
    CrossrefPubMedGoogle Scholar
  • 41 Schalm S W, Heathcote J, Cianciara J. et al . Lamivudine and alfa interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.  Gut. 2000;  46 (4) 562-568 (Ib)
    CrossrefPubMedGoogle Scholar
  • 42 Barbaro G, Zechini F, Pellicelli A M. et al . Long-term efficacy of interferon alfa-2 b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.  J Hepatol. 2001;  35 (3) 406-411 (Ib)
    CrossrefPubMedGoogle Scholar
  • 43 Schiff E R, Dienstag J L, Karayalcin S. et al . Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.  J Hepatol. 2003;  38 (6) 818-826 (Ib)
    CrossrefPubMedGoogle Scholar
  • 44 Santantonio T, Niro G A, Sinisi E. et al . Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study.  J Hepatol. 2002;  36 (6) 799-804 (Ib)
    CrossrefPubMedGoogle Scholar
  • 45 Peters M, Hann H W, Martin P. et al . Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis.  Gastroenterology. 2004;  126 (1) 91-101 (Ib)
    CrossrefPubMedGoogle Scholar
  • 46 Chan H L, Tang J L, Tam W. et al . The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis.  Aliment Pharmacol Ther. 2001;  15 (12) 1899-1905 (Ia)
    CrossrefPubMedGoogle Scholar
  • 47 Mutchnick M G, Lindsay K L, Schiff E R. et al . Thymosin alfa1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study.  J Viral Hepat. 1999;  6 (5) 397-403 (Ib)
    CrossrefPubMedGoogle Scholar
  • 48 Cotonat T, Quiroga J A, Lopez-Alcorocho J M. et al . Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.  Hepatology. 2000;  31 (2) 502-506 (IIa)
    CrossrefPubMedGoogle Scholar
  • 49 Dahmen A, Herzog-Hauff S, Bocher W O. et al . Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B.  J Med Virol. 2002;  66 (4) 452-460 (IIa)
    CrossrefPubMedGoogle Scholar
  • 50 Heintges T, Petry W, Kaldewey M. et al . Combination therapy of active HBsAg vaccination and interferon-alfa in interferon-alfa nonresponders with chronic hepatitis B.  Dig Dis Sci. 2001;  46 (4) 901-906 (IIa)
    CrossrefPubMedGoogle Scholar
  • 51 Carreno V, Zeuzem S, Hopf U. et al . A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B.  J Hepatol. 2000;  32 (2) 317-324 (Ib)
    CrossrefPubMedGoogle Scholar
  • 52 Cohard M, Poynard T, Mathurin P. et al . Prednisone-interferon combination in the treatment of chronic hepatitis B: direct and indirect metaanalysis.  Hepatology. 1994;  20 (6) 1390-1398 (Ia)
    CrossrefPubMedGoogle Scholar
  • 53 Zarski J P, Causse X, Cohard M. et al . A randomized, controlled trial of interferon alfa-2 b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group.  J Hepatol. 1994;  20 (6) 735-741 (Ib)
    CrossrefPubMedGoogle Scholar
  • 54 Krogsgaard K. Does corticosteroid pretreatment enhance the effect of alfa interferon treatment in chronic hepatitis B?.  J Hepatol. 1994;  20 (2) 159-162 (IV)
    CrossrefPubMedGoogle Scholar
  • 55 Perrillo R P. Chronic hepatitis B: problem patients (including patients with decompensated disease).  J Hepatol. 1995;  22 (1 Suppl.) 45-48 (Ia)
    PubMedGoogle Scholar

Prof. Dr. med. Michael P. Manns

Direktor der Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Email: Manns.Michael@mh-hannover.de

      >